Good point. Share structure with VVUS isn't too different (ELTP has about 25 million more shares), but they're trading very disproportionately. I guess Qnexa and diet drugs are more sexy than the generics. But folks, we're talking about Elite selling oxycodone. ELI-154 and ELI-216 will be major, major products for this company. I have zero doubts that Elite will get these two drugs to market and will be getting partnerships with milestone payments and/or royalties or else Elite will be snatched up at a premium. This is a company where you can park some money, and one day you wake up to an FDA approval and a major gap up. Happens more than one might think. I really, really like my chances here with Elite.
News 
Market Data 
Discover 
